![](https://endpts.com/wp-content/uploads/2022/10/Erik-van-den-Berg.jpg)
Erik van den Berg, Memo Therapeutics CEO
Memo Therapeutics refuels with $22M to expand trial for infection-fighting antibody in kidney transplant recipients
Swiss biotech Memo Therapeutics raised $22 million (CHF 20 million) in a Series C extension to develop an antibody treatment for BK polyomavirus (BKV) infection …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.